Abstract Cardiovascular–kidney–metabolic (CKM) syndrome represents a continuum of interrelated adiposity, insulin resistance, cardiovascular disease, kidney dysfunction, and metabolic disturbances that evolve across the lifespan. Emerging evidence demonstrates that both biological sex and sociocultural gender significantly shape CKM risk, progression, and clinical expression. CKM syndrome pathogenesis reflects complex multisystem interactions involving adipose tissue dysfunction, neurohormonal activation, inflammatory signaling, and vascular impairment, all of which exhibit important sex-specific patterns. This review examines CKM syndrome from a sex- and gender-informed perspective, highlighting how endogenous and exogenous sex hormones, reproductive transitions, pregnancy-related complications, and dietary exposures shape the long-term CKM syndrome risk. Particular attention is given to the roles of estrogen and testosterone in modulating adipose biology, vascular function, and metabolic regulation. Polycystic ovary syndrome is discussed as a model of androgen excess and multisystem metabolic vulnerability that accelerates CKM features. Finally, we address brain vulnerability within CKM syndrome, emphasizing shared inflammatory, vascular, and neuroendocrine mechanisms linking metabolic dysfunction to cognitive decline and neuropsychiatric disorders. Recognizing these interconnected and sex-specific influences is critical for advancing precision prevention and treatment strategies across the CKM syndrome spectrum. Graphical abstract
A workgroup assembled by the Alzheimer's Association recently described a conceptual framework for Alzheimer's disease biological staging based on amyloid and tau PET imaging. However, specific tau PET cut points were left to be determined, a step necessary prior to clinical application. We sought to operationalize and evaluate Alzheimer's disease biological staging by identifying meaningful tau PET cut points to define the four biological stages in a well-characterized participant cohort and describe the features of individuals placed into the different biological stages. The primary analysis included 896 participants in the Mayo Clinic Study of Aging or the Mayo Clinic Alzheimer's Disease Research Center longitudinal cohorts. A validation cohort consisted of 328 participants in the Alzheimer's Disease Neuroimaging Initiative. Both cognitively normal and impaired individuals with positive amyloid PET and evaluable tau PET imaging were included. Tau PET cut points were identified with Gaussian mixture models to characterize Alzheimer's disease biological stage in study participants with different clinical diagnoses and objective degrees of cognitive impairment as measured by Mini-Mental State Examination. A tau PET cut point in the medial temporal region and two cut points in the temporoparietal region were identified to produce, collectively, the four Alzheimer's disease biological stages described in the revised criteria. Increasing stage was associated with greater likelihood of mild cognitive impairment and dementia diagnosis and worsening cognitive performance on Mini-Mental State Examination and Clinical Dementia Rating Sum of Boxes, a result that was reproduced in the independent Alzheimer's Disease Neuroimaging Initiative cohort. This study provided empirical validation for the concept of using amyloid PET and tau PET to separate subjects with biomarker-proven Alzheimer's disease into four biological stages with distinct characteristics.
Importance:The management of patent ductus arteriosus (PDA) in preterm infants is controversial. Objective:To determine whether expectant management compared with active treatment of a protocol-defined PDA in preterm infants decreases the incidence of death or bronchopulmonary dysplasia (BPD). Design, Setting, and Participants:A randomized clinical trial including infants born at 22 to 28 weeks' gestation and diagnosed with a protocol-defined PDA between the age of 48 hours and 21 days at screening. The trial was conducted from December 2018 to December 2024 at 33 hospitals within the National Institute of Child Health and Human Development Neonatal Research Network. The final date of follow-up was June 2025. Interventions:Infants with PDA were randomized to expectant management (n = 242) or active treatment (n = 240; acetaminophen, ibuprofen, or indomethacin) to close the PDA. Main Outcomes and Measures:The primary outcome was death or BPD at 36 weeks' postmenstrual age. The secondary outcomes included the components of the primary outcome and other morbidities of prematurity. Results:A total of 482 infants were randomized (median gestational age, 25 weeks [IQR, 24 to 27 weeks]; median birth weight, 760 g [IQR, 620 to 935 g]). The trial was stopped for futility and safety after the 50% interim analysis for the primary outcome due to higher survival in the expectant management group. The incidence of death or BPD was 80.9% (195/241) of infants in the expectant management group vs 79.6% (191/240) of infants in the active treatment group (adjusted risk difference, 1.2% [95% CI, -5.7% to 8.1%]; P = .73). The incidence of death before 36 weeks' postmenstrual age was 4.1% (10/241) of infants in the expectant management group vs 9.6% (23/240) of infants in the active treatment group (adjusted risk difference, -5.6% [95% CI, -10.1% to -1.2%]; P = .01). Infections resulting in death occurred in 0.8% (2/241) of infants in the expectant management group vs 3.8% (9/240) of infants in the active treatment group. Conclusions and Relevance:In extremely preterm infants with a protocol-defined PDA, death or BPD did not differ between the expectant management group and the active treatment group. Survival was substantially higher with expectant management. Trial Registration:ClinicalTrials.gov Identifier: NCT03456336.
Hypertension remains a leading cause of cardiovascular morbidity and mortality in the United States. The 2025 American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of High Blood Pressure in Adults provides the first major update since 2017. It reveals new evidence in the diagnosis, risk assessment, and treatment of hypertension. This review summarizes key updates, contrasts them with prior recommendations, and discusses implications for clinical practice. The 2025 AHA/ACC Hypertension Guideline introduces several major updates that reshape risk assessment, diagnosis, and treatment strategy. Adoption of the PREVENT risk calculator replaces the pooled cohort equations, improving cardiovascular risk estimation by incorporating renal function, statin use, and social drivers of health. Screening for primary aldosteronism is expanded to all patients with stage 2 or resistant hypertension, addressing underdiagnosis of this secondary cause. Renal denervation is introduced as an adjunctive option for select patients with resistant hypertension. The guideline also provides expanded recommendations for special populations, including those with chronic kidney disease, diabetes, pregnancy, and neurologic disorders. Enhanced emphasis on home blood pressure monitoring, lifestyle modification, and team-based care highlights the growing importance of patient engagement and coordinated care. The 2025 AHA/ACC Hypertension Guideline marks a pivotal shift toward risk-based, patient-centered hypertension management. It reinforces the need for tailored strategies that bridge clinical practice and population health. Effective implementation will depend on interdisciplinary collaboration and equitable access to preventative and therapeutic resources.
Abstract Biological sex is an under recognized determinant of cerebrovascular physiology with direct implications for therapeutic development in Alzheimer's disease (AD). Emerging evidence shows that sex-specific hormonal, genetic, epigenetic, and structural factors shape key regulatory mechanisms of cerebral blood flow (CBF)—including myogenic reactivity, endothelial signaling, neurovascular coupling, and metabolic vasoregulation. Estrogen enhances nitric oxide and epoxyeicosatrienoic acid (EET)–mediated vasodilation, stabilizes endothelial and smooth-muscle Ca 2+ signaling, and preserves neurovascular coupling; its abrupt loss after menopause accelerates arterial stiffening, impairs autoregulation, and increases susceptibility to hypoperfusion-related neurodegeneration. Testosterone and progesterone exert distinct and dose-dependent cerebrovascular effects, influencing baseline tone, inflammatory signaling, and small-vessel vulnerability in males and females. Sex-dependent interactions with key AD-related pathways—including APOE genotype, amyloid and tau accumulation, oxidative stress, and blood–brain barrier dysfunction—further contribute to divergent perfusion trajectories and clinical manifestations. Despite these mechanistic insights, sex remains insufficiently integrated into biomarker development, target validation, and therapeutic trial design. Incorporating sex-specific cerebrovascular phenotypes may refine the use of imaging modalities (ASL-MRI, PET), enhance the development of CBF-modulating agents (e.g., sEH inhibitors, 20-HETE pathway modulators, endothelial-targeted therapies), and support precision approaches to hormone-based or vascular-targeted interventions. Understanding how biological sex influences CBF regulation across the lifespan is essential for advancing vascular-focused drug discovery and improving individualized therapeutic strategies for AD.